Ontvang nu dagelijks onze kooptips!

word abonnee
IEX 25 jaar
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
Markt vandaag Koersen Forum Premium IEX Expert
Home  /   Forum   /   BioPharma   /   Genmab, de Deense parel

BioPharma« Terug naar discussie overzicht

Genmab, de Deense parel

Volgen
3.541 Posts
Pagina: «« 1 ... 4 5 6 7 8 ... 178 »» | Laatste | Omlaag ↓
  2. op&neer 15 juni 2010 08:04
    June 14 (Bloomberg) -- Genmab A/S rose the most in almost a decade in Copenhagen trading after an analyst said the biotechnology company is undervalued, making it a takeover target for GlaxoSmithKline Plc.

    “The stock value is so low it makes sense for GSK to make an offer for the entire company,” Peter Aabo, founder of BiotekAnalyse, said today by phone. AktieUgebrevet ApS published Aabo’s analysis of Copenhagen-based Genmab today in its weekly investor newsletter.

    Genmab’s cash and short-term investments equal almost half its market value of about 2.6 billion kroner ($431.2 million), indicating the market is undervaluing the company, Aabo said. Data for its experimental cancer treatment zalutumumab are probably strong enough to lead to U.S. approval either next year or in 2012, he said. An acquirer probably would offer 150 kroner to 200 kroner a share, Aabo said. At the higher price, a bid would value Genmab at as much as 9 billion kroner.

    Genmab gained 14.44 kroner, or 33 percent, to close at 58.15 kroner. The gain was the biggest ever for the company, which sold shares in an initial public offering in October 2000. Genmab has never posted an annual profit.

    “This is just a story that has been around for very long time,” said Henrik Aagaard-Jensen, a sales trader at Jyske Bank A/S in Silkeborg, Denmark. “We don’t believe that Glaxo would make a bid as they have partnership agreements with Genmab in place.”

    Claire Brough, a spokeswoman at Glaxo, which owns a stake of just below 10 percent in the company, declined to comment. Helle Husted, a spokeswoman for Genmab, declined to comment on whether it had been approached by Glaxo, citing the company’s communication policy.

    Belangrijkste zin is:
    An acquirer probably would offer 150 kroner to 200 kroner a share, Aabo said. At the higher price, a bid would value Genmab at as much as 9 billion kroner.

  3. op&neer 15 juni 2010 13:29
    Er komt eindelijk leven in de brouwerij. Het lijkt me dat de bodem is gezet. Er zal nu een hobbelig herstel volgen richting de intrinsieke waarde die toch echt nog wel 100% hoger ligt dan de huidige koers..

    Genmab CEO quits Danish biotech under fire
    Tue Jun 15, 2010 6:12am EDTStocks

    * Departure follows criticism of strategy, slump in shares

    * Genmab's scientific head Van de Winkel named new CEO

    * Analyst says move suggests Glaxo bid for firm unlikely

    * Shares up 3 percent (Adds analyst comment, shares, background)

    By Peter Levring

    COPENHAGEN, June 15 (Reuters) - The chief executive of Genmab (GEN.CO) stepped down on Tuesday following criticism of recent mis-steps at the Danish biotechnology company, whose shares have fallen more than 80 percent in the past three years.

    Dutchman Jan van de Winkel, the company's chief scientific officer since its inception, will replace American Lisa Drakeman as CEO with immediate effect, the company said.

    Genmab was for many years a rising star of the European biotech sector, thanks to the successful development of its Arzerra medicine for blood cancers and a multibillion-dollar licensing deal for the drug with GlaxoSmithKline (GSK.L).

    But more recently clinical trial results have disappointed and the company has twice had to make significant cost cuts. It also decided last year to sell a U.S. drugmaking facility, marking an embarrassing reversal of a less than two-year-old strategy to secure its own manufacturing capacity.

    The company's problems have led to persistent speculation that Glaxo might buy it to get full rights to Arzerra. But many analysts are sceptical.

    "To me Drakeman's exit shows a GSK takeover of Genmab is not imminent. If it had been just around the corner she would have seen it through. It would have left her with a better reputation," said Sydbank analyst Rune Dahl.

    A spokeswoman for Glaxo declined to comment.

    Shares in Genmab had risen sharply on Monday following a bullish analysis in a newsletter that highlighted talk of a Glaxo takeover, as well as positive results for candidate drug zalutumumab.

    Genmab shares, which last Thursday hit their lowest level since mid-2003, were up 3 percent to 60 crowns by 0945 GMT.

    Glaxo bought global rights to Arzerra in December 2006 in a deal worth up to $2.1 billion, a record sum for a biotech product agreement at the time.

    Genmab said it would hold a conference call to discuss the management changes at 1400 GMT. The timing will allow participation of the company's American chairman, Michael Widmer, who is based on the U.S. West Coast. (Writing by Ben Hirschler; Editing by Michael Shields)
  7. h980577. 16 augustus 2010 22:43
    Morgen NABEURS cijfers en outlook uit.

    Voor een ieder die nog wil instappen op de grotere transparantie die wordt geboden.

    Qua liquiditeiten lijkt het (wanneer het geld van de nieuwe deal met Glaxo) binnen is een minder groot issue, dit was vooral de onzekerheid waarop de daling plaatsvond.

    Koers inmiddels 67dkk van een low van 40dkk begin juli 2010

    Highs nog steeds ver weg, 300dkk een kleine 2 jaar geleden.

    Ps positie in sprinters Genmab
  10. sheriff Grover 18 augustus 2010 23:23
    Ik ben maar gestopt met te bedenken waarom dat de koers maar steeds weer zakt .... enkele :

    2 trials verknald , een plant die aan de straatstenen niet meer te slijten is en minimaal $100 tot $150 miljoen verlies oplevert , imo tegenvallende Arzerra sales DKR 115 miljoen in het eerste half jaar wat al met al een kleine $4 miljoen aan royalties oplevert. Gedoe met die CEO Lisa Drakeman and last but not least lijkt een overname door GSK verder weg dan ooit .

    Sheriff Grover
  11. h980577. 17 september 2010 14:38
    "Topman Van de Winkel gaf ook aan dat zijn bedrijf een scenario voor een tweede notering bekijkt, eventueel aan Euronext of op de Amerikaanse Nasdaq. ,,Maar dat heeft op dit moment helemaal geen prioriteit'', zo benadrukte hij. De onderneming had eerder een tweede notering in Frankfurt, maar deze werd eind 2002 opgeheven."

    Huh....deze notering staat toch echt nog bij Binck... (xetra)

    Laatste 8,0100 10:51 150
    +/- -0,4100 -4,83%
    Slot 8,4200 16-09-10
    Open 8,0100 10:51
    Hoog 8,0100 10:51
    Laag 8,0100 10:51
    Bied 8,0400 13:19 150
    Laat 8,3200 13:19 2.500
    Volume 150

    En de grafiek stopt niet in 2002... :)

    Ps voor de nieuwsgierigen, deze uitspraak van dhr. Vd Winkel staat in de volgende link:

    www.iex.nl/nieuws/nieuws_artikel.asp?...

  12. h980577. 13 oktober 2010 19:55
    Genmab Announces Antibody Development Collaboration with Lundbeck
    Copenhagen, Denmark; October 13, 2010 – Genmab A/S (OMX: GEN) announced today an agreement to create and develop human antibody therapeutics for disorders of the central nervous system (CNS) with H. Lundbeck A/S. Genmab will create novel human antibodies to three targets identified by Lundbeck. Lundbeck will have access to Genmab’s antibody creation and development capabilities, including its state of the art, fully automated pre-clinical antibody screening and characterization capabilities and its proprietary stabilized IgG4 and UniBody therapeutic antibody platforms. Lundbeck will have an option to take selected antibodies into clinical development at its own cost and subject to the payment of milestones and single-digit royalties to Genmab upon successful development and commercialization. Genmab will have a similar option to take selected antibodies into clinical development for cancer indications at its own cost and subject to the payment of milestones and single-digit royalties to Lundbeck.

    Under the terms of the agreement, Genmab will receive an upfront payment of €7.5 million (approximately DKK 56 million). Lundbeck will fully fund the development of the antibodies. If all milestones in the agreement are achieved, the total value of the agreement to Genmab would be approximately €38 million (approximately DKK 283 million), plus single-digit royalties.



    “We are pleased to enter into this collaboration with Lundbeck, world experts in the development of CNS therapeutics. It gives Genmab the opportunity to leverage our antibody technology and expertise and to expand our pipeline into a new and exciting therapeutic area without assuming a financial obligation,” said Jan van de Winkel, Chief Executive Officer of Genmab.



    “Genmab’s broad antibody development expertise and Lundbeck’s knowledge in CNS disorders is an ideal combination for developing new treatments in this important therapeutic area,” said Peter Høngaard Andersen, Executive Vice President, Head of Research at Lundbeck. “The new partnership follows Lundbeck’s new R&D strategy to ensure we have the most efficient platform for the future discovery and development of drugs that will be able to help and treat biologically defined groups of patients with brain diseases. It is this type of drugs we expect will be in demand in the future.”



    This agreement is not expected to have a material impact on Genmab’s 2010 financial guidance.
  13. [verwijderd] 19 oktober 2010 06:41
    Genmab Announces Update on Zalutumumab

    • Genmab has received preliminary feedback from selected national European regulatory authorities and FDA on zalutumumab
    • Genmab believes a MAA for zalutumumab in second line head and neck cancer could be pursued based on available clinical data
    • Additional clinical study data would be required prior to a US regulatory submission

    Copenhagen, Denmark; October 18, 2010 – Genmab A/S (OMX: GEN) announced today an update on the potential regulatory pathway for zalutumumab following preliminary, non-binding discussions with a number of selected national European regulatory authorities and the FDA. Based on overall feedback from regulatory authorities in Europe, Genmab believes a Marketing Authorization Application (MAA) for zalutumumab could be pursued based on the data from the Phase III study in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) who failed standard platinum-based therapy, reported earlier this year. Additional clinical study data would, however, be required prior to submitting a regulatory application in the US.

    “Our discussions with the regulatory authorities have been very productive and we are encouraged by the overall feedback we have received,” said Prof. Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab. “We are advancing our partnership discussions in earnest and feel confident that our potential future development partner would be able to move forward with a European regulatory filing for zalutumumab.”

    www.genmab.com/Press%20Center/RecentN...
  14. sheriff Grover 19 november 2010 14:53
    Geachte hr Wijma wanneer kunnen wij weer eens een update re. Genmab van U verwachten ?? Het is nu al een bijna een jaar geleden dat wij van U hebben mogen vernemen . Het is inmiddels wel duidelijk dat het bedrijf de door u geschatte $100 miljoen niet zal halen en een noodzaak voor een overname door GSK bij deze Arzerra omzetten lijkt ook al niet aanwezig ...
    Is Arzerra niet het beloofde wondermiddel of zijn er andere aanwijsbare redenen voor de imo zwaar tegenvallende omzetten ??

    bvd & vrgr , sheriff Grover
  15. [verwijderd] 20 januari 2011 15:02

    Genmab Provides Detailed Pipeline and Technology Update at Today’s R&D Day

    • Ofatumumab updates on trials, anticipated timelines and clinical experience
    • Pre-clinical combination treatment data for daratumumab
    • New data on the HuMax-TF Antibody-Drug Conjugate (ADC) program
    • Update on next generation bispecifics platform

    Copenhagen, Denmark; January 20, 2011 – Genmab A/S (OMX: GEN) will present a comprehensive update on its clinical pipeline, pre-clinical portfolio and next generation antibody technologies at its R&D Day to be held today at its research facilities in Utrecht, the Netherlands. Today’s presentations will be available via live webcast at 1:30PM CET at www.genmab.com.

    Highlights will include:

    • Discussion of ongoing ofatumumab trials including clinical study initiation and data timelines. An interim analysis of the Phase II study of ofatumumab in combination with ICE or DHAP chemotherapy in relapsed/refractory diffuse large B cell lymphoma (DLBCL) has been conducted in collaboration with GlaxoSmithKline (GSK).

    “We recently performed a pre-planned interim analysis for futility of our Phase II ofatumumab study in relapsed or refractory DLBCL. The analysis showed that the pre-specified minimum response rate was met or exceeded, clearly warranting continued recruitment into the study and we hope that we will be able to present primary endpoint data from this important study later this year,” said Klaus Edvardsen, Project Physician leader for ofatumumab at GSK.

    • A clinician’s perspective on ofatumumab. Dr. Myron Czuczman, Professor of Medicine, State University of New York at Buffalo, and Chief, Lymphoma/Myeloma Service at Roswell Park Cancer Institute, will present his experience to date of treating cancer patients with ofatumumab.

    • Pre-clinical data from the daratumumab program. In pre-clinical studies, daratumumab has shown enhanced efficacy in killing multiple myeloma cells in combination with existing chemotherapy regimens. Data from the Phase I/II study is expected in 2011 and combination studies are being planned.

    • Updates on the zalutumumab, RG4930 and RG1512 programs. A Phase II study of RG1512 in cardiovascular disease was initiated by Genmab’s partner, Roche, in December 2010.

    • Pre-clinical portfolio update including early encouraging in vitro and in vivo data from the HuMax-TF™ ADC program in collaboration with Seattle Genetics.

    • Exploration of Genmab’s proprietary, next-generation antibody technologies. Our bispecifics platform, DuoBody™, is uniquely based on a natural process that efficiently generates stable human antibodies that have the ability to bind two targets in a single molecule and may remain in the body as long as regular human antibodies. This novel format may represent a next wave in therapeutic antibody development, leading to increased efficacy and improved specificity of future antibody therapies.

    “Genmab’s success is dependent upon our ability to develop and access innovative technologies and create differentiated therapeutic products,” said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab. “I’m delighted to have the opportunity to share our progress in these areas and to showcase our state-of-the-art research and development facilities here in Utrecht.”

    Today’s presentation will also be available by webcast replay approximately one hour following conclusion of the event

    www.genmab.com/Press%20Center/RecentN...
  18. sheriff Grover 13 maart 2011 10:34
    Het heeft allemaal meer weg van een wanhopige poging het aandeel niet verder te laten zakken als je het mij vraagt . Wat erger is dat er dus hoogstwaarschijnlijk weinig positiefs in de nabije toekomst ligt dus geen overname (zelfs niet met deze koersen al was onze ceo daar nog doodsbenauwd voor in oktober!)en ook geen zaluovereenkomst ...
    We mogen blij zijn dat dhr Stienstra nog niet de handdoek heeft gegooid anders staan we op 30 DKR !!

    gr sheriff Grover
  19. [verwijderd] 22 juni 2011 16:13
    Op de site van Genmab staan de insider trades van het management. Al ruim voordat er ook maar een produkt op de markt kwam (arzerra) hebben sommigen al behoorlijk gecashed (kijk bv bij 15 februari 2007) Heb zelf dus onvoldoende DD gedaan voordat ik in 2007 aandelen genmab kocht(voor de hoofdprijs van dkr 330). Als je dan later in interviews met vd Winkel leest dat ze er een hele grote winkel van gaan maken, heeft ie toch nog gelijk gehad. Voorlopig verdienen ze nog steeds meer met de handel in aandelen dan met het bedrijf zelf. Als ik ongelijk heb, dan hoor ik het graag.
3.541 Posts
Pagina: «« 1 ... 4 5 6 7 8 ... 178 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Markt Vandaag

Stijgers

instrument koers absoluut verschil relatief verschil
B&S Group SA 4,395 +0,34 +8,25%
Galapagos 25,380 +1,42 +5,93%
EBUSCO HOLDING 0,925 +0,05 +5,16%
ALLFUNDS GROUP 5,430 +0,27 +5,13%
BESI 112,800 +5,30 +4,93%
THEON INTERNAT 10,340 +0,48 +4,87%
RENEWI 7,150 +0,24 +3,47%
UNILEVER PLC 56,440 +1,88 +3,45%
RELX 44,820 +1,42 +3,27%
FASTNED 21,300 +0,65 +3,15%
Pharming 0,716 +0,02 +3,02%
Wolters Kluwer 157,950 +4,60 +3,00%
WDP 20,720 +0,60 +2,98%
UMG 22,580 +0,63 +2,87%
CTP 15,100 +0,40 +2,72%
DSM FIRMENICH AG 107,250 +2,40 +2,29%
INPOST 17,210 +0,35 +2,08%
SIGNIFY NV 21,740 +0,44 +2,07%
IMCD 140,150 +2,80 +2,04%
Eurocommercial Properties 23,300 +0,45 +1,97%
Fagron 18,620 +0,34 +1,86%
ADYEN NV 1.290,400 +23,40 +1,85%
ASML 642,100 +10,60 +1,68%
ASMI 504,600 +8,20 +1,65%
Ahold Delhaize 32,830 +0,52 +1,61%
AEX 879,80 +13,67 +1,58%
Kendrion 10,900 +0,16 +1,49%
JDE PEET'S 18,600 +0,23 +1,25%
OCI 11,315 +0,13 +1,16%
Heineken 70,640 +0,76 +1,09%
ACOMO 17,640 +0,18 +1,03%
Sif Holding 12,220 +0,12 +0,99%
AMX 866,26 +8,37 +0,98%
NX FILTRATION 4,240 +0,04 +0,95%
Avantium 2,170 +0,02 +0,93%
EXOR NV 95,200 +0,85 +0,90%
Brunel 8,470 +0,07 +0,83%
ASCX 1.183,15 +9,48 +0,81%
RANDSTAD NV 40,610 +0,31 +0,77%
Nedap N.V. 52,400 +0,40 +0,77%
Philips Koninklijke 25,220 +0,19 +0,76%
Sligro 10,660 +0,08 +0,76%
Corbion 21,980 +0,16 +0,73%
Arcadis 62,200 +0,45 +0,73%
AALBERTS NV 34,100 +0,22 +0,65%
ASR Nederland 45,130 +0,29 +0,65%
Vastned 24,250 +0,15 +0,62%
Wereldhave 14,120 +0,08 +0,57%
KPN 3,620 +0,02 +0,56%
Aegon 5,960 +0,03 +0,51%
TomTom 5,200 +0,03 +0,48%
Akzo Nobel 55,880 +0,26 +0,47%
ArcelorMittal 23,990 +0,08 +0,33%
SHELL PLC 31,610 +0,09 +0,27%
NSI 19,700 +0,04 +0,20%
Accsys 0,555 +0,00 +0,18%
HEIJMANS KON 27,950 +0,05 +0,18%
Fugro 16,900 +0,03 +0,18%
AMG Critical Materials N.V. 14,980 +0,01 +0,07%
PostNL 1,009 0,00 0,00%

Dalers

instrument koers absoluut verschil relatief verschil
EBUSCO (RIGHT) 0,000 -0,16 -99,81%
SBM Offshore 17,720 -0,30 -1,66%
CM.COM 6,000 -0,10 -1,64%
JUST EAT TAKEAWAY 14,010 -0,23 -1,58%
Alfen N.V. 11,245 -0,17 -1,45%
Vopak 45,100 -0,60 -1,31%
Flow Traders 21,380 -0,28 -1,29%
BAM 4,010 -0,05 -1,23%
ING 14,652 -0,17 -1,16%
ForFarmers 3,280 -0,03 -0,91%
Van Lanschot Kempen NV 43,100 -0,35 -0,81%
ABN AMRO BANK N.V. 14,735 -0,12 -0,77%
AZERION 1,266 -0,01 -0,63%
Air France-KLM 7,358 -0,05 -0,62%
TKH 31,720 -0,18 -0,56%
NN Group 44,640 -0,20 -0,45%
Basic-Fit 21,500 -0,08 -0,37%
PROSUS 37,970 -0,13 -0,35%
Aperam 27,560 -0,06 -0,22%
vlag naam koers verschil relatief verschil
AEX 879,80 +13,67 +1,58%
AEX GR 3.450,86 +53,61 +1,58%
Germany40^ 19.354,60 +208,43 +1,09%
FTSE 100 8.262,08 +112,81 +1,38%
EURO50 4.797,55 0,00 0,00%
US30^ 44.302,90 0,00 0,00%
Nasd100^ 20.778,50 0,00 0,00%
US500^ 5.965,55 0,00 0,00%
Japan225^ 38.598,50 0,00 0,00%
VD-NEW 16,06 -0,99 -5,82%
#/^ Index indications calculated real time, zie disclaimer